Overview

Study of FK778 in Renal Transplant Recipients With Untreated BK Nephropathy

Status:
Terminated
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and effectiveness of a new oral immunosuppressant agent compared to standard care in renal transplant patients diagnosed with BK nephropathy.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
Astellas Pharma US, Inc.